

NEWS RELEASE

13th November 2018, Mumbai - India

Performance Highlights- Consolidated for H1 FY 2018-19 Results

Marksans Consolidated Revenue at Rs. 506.73 crores in H1 FY 2018-19

- EBITDA was Rs 75.04 crores for the period, as compared to Rs.53.63 crores last year same period, registering growth of 39.92% over last year.
- Profit Before Tax was Rs.58.08 crores for the period, as compared to Rs.34.23 crores during last year same period, registering growth of 69.68% over last year.
- Profit after Tax was Rs.43.46 crores for the period, as compared to Rs.23.06 crores last year same period, registering growth of 88.46% over last year.

Management Discussion and Analysis for the H1 FY 2018-19

Revenue Figures - Consolidated

INR in cro				
		H1 FY 2018-19		
	H1 FY	H1 FY	Growth %	Mix %
	2018-	2017-		
	2019	2018		
Europe, UK – Formulations	242.10	237.40	1.98%	47.78%
US & North America -Formulations	191.19	189.58	0.85%	37.73%
Australia & NZ – Formulations	58.24	51.53	13.02%	11.49%
Rest of World(ROW)	15.20	16.40	-7.29%	3.00%
Consolidated Revenue from operations	506.73	494.91	2.39%	100.00%

Business Highlights

- Company achieved revenue of Rs. 242.10 crores from Europe, UK Formulation business as compared to Rs. 237.40 crores achieved during last year same period, registering growth of Rs.1.98%.
- US & North America Formulation business reported revenue of Rs. 191.19 crores, as against Rs.189.58 crores during last year same period registering growth of 0.85%.
- Australia & NZ Formulation business achieved revenue of Rs. 58.24 crores as compared to Rs.51.53 crores during last year same period registering growth of 13.02%.
- Rest of World Formulation business was Rs. 15.20 crores. Almost 97% of company's total revenue came from regulated markets of US, Europe, Australia & Canada.

CIN: L24110MH1992PLC066364

www.marksanspharma.com



About Marksans Pharma Limited

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Marksans may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Marksans Pharma Limited
11th Floor, "GRANDEUR", Veera desai Extension Road,
Oshiwara, Andheri – (West), Mumbai – 400 053, India
Tel:- +91 22 4001 2000, Fax:- +91 22 4001 2011.



CIN: L24110MH1992PLC066364

www.marksanspharma.com